GTBP
GT Biopharma, Inc.
$0.4180
-1.65%
$15.3M
No data for this timeframe.
Vol
Market Cap$15.3M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$27.2K
Inst. Activity2 buys / 0 sells
SEC Reports3
Press Releases1
Recent Activity
May 22, 2026
SEC
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regai
8-K — Impact 7/10
Apr 30, 2026
SEC
GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock for resale by sellin
S-1 — Impact 7/10
Apr 7, 2026
SEC
GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor
8-K — Impact 4/10
Inst.
MORGAN STANLEY — ADD
18,599 shares ($14.6K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
16,037 shares ($12.6K)
Jun 9, 2026
short_volume
Short Volume: GTBP — 60.2% short (0.4M / 0.6M)
Short: 371,875 | Exempt: 0 | TRF Vol: 618,188 | Short Ratio: 60.2% | Off-exchange volume (dark pool
Mar 2, 2026
Press
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss
Impact 5/10
Price Targets
Historical data — last covering-analyst action Dec 2024. No current recommendation available.
$3.00 (Dec 2024)
Current $0.4180
Low $3.00
Median $3.00
High $3.00
1 analysts
$3.00
$3.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 2, 2024 | Roth MKM | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 | $-0.08 — $-0.08 | 85% YoY | 1 |
| Next Q | $-0.08 | $-0.08 — $-0.08 | 90% YoY | 1 |
| Current FY | $-0.34 ▼ -6.3% | $-0.34 — $-0.34 | 95% YoY | 1 |
| Next FY | $-0.27 ▼ -3.8% | $-0.27 — $-0.27 | 21% YoY | 1 |
Latest Reports
BEARISH
8-K
7/10
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regai
May 22, 2026
BEARISH
S-1
7/10
GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock for resale by sellin
Apr 30, 2026
MIXED
Press
5/10
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss
Mar 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $14.6K | ADD |
| WELLS FARGO & COMPANY/MN | $12.6K | ADD |
| BANK OF AMERICA CORP | $19.00 | — |
3 institutional holders with $27.2K total value (34,660 shares) as of 2025-Q4. Top holders: MORGAN, WELLS, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 18,599 | $14.6K | 53.7% | ADD +32.7% |
| 2 | WELLS FARGO & COMPANY/MN | 16,037 | $12.6K | 46.3% | ADD +60.2% |
| 3 | BANK OF AMERICA CORP /DE/ | 24 | $19.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 14,015 | 18,599 | +32.7% | $14.6K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,012 | 16,037 | +60.2% | $12.6K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 4,015 | 14,015 | +249.1% | $8.2K | 2025-Q3 |
| UBS Group AG | TRIM | 5,810 | 2,626 | -54.8% | $1.5K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 26,300 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 26,300 | — | $94.2K | 2025-Q2 |
| UBS Group AG | DOUBLED | 2,559 | 5,810 | +127.0% | $20.8K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 20,138 | — | $45.1K | 2025-Q1 |
| UBS Group AG | TRIM | 4,996 | 2,559 | -48.8% | $5.5K | 2025-Q1 |
| UBS Group AG | ADD | 3,903 | 4,996 | +28.0% | $15.2K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 266 | 3,533 | +1228.2% | $10.8K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
8-K
7/10
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until Novembe
May 22, 2026
BEARISH
S-1
7/10
GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock
Apr 30, 2026
NEUTRAL
8-K
4/10
GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of
Apr 7, 2026
Historical analyst distribution (last covering-analyst action Dec 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2024. No current recommendation available.
$3.00 mean target (Dec 2024)
$3.00 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4180 |
| Target Low | $3.00 |
| Target Mean | $3.00 |
| Target Median | $3.00 |
| Target High | $3.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | 85.5% | +0.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.08 | 90.4% | +0.0% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.34 | $-0.34 | $-0.34 | 94.9% | -6.3% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.27 | $-0.27 | $-0.27 | 20.6% | -3.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $-0.080 | |
| 30d ago | $-0.080 | |
| 60d ago | $-0.080 | |
| 90d ago | $0.000 | -0.080 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 2, 2024 | Roth MKM | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: GTBP — 60.2% short (0.4M / 0.6M)
Short: 371,875 | Exempt: 0 | TRF Vol: 618,188 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: GTBP — 63.2% short (0.5M / 0.9M)
Short: 547,662 | Exempt: 74,158 | TRF Vol: 866,346 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: GTBP — 63.7% short (0.4M / 0.7M)
Short: 442,831 | Exempt: 32,599 | TRF Vol: 695,403 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: GTBP — 63.2% short (0.7M / 1.0M)
Short: 654,011 | Exempt: 14,700 | TRF Vol: 1,034,149 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: GTBP — 62.4% short (0.4M / 0.6M)
Short: 359,677 | Exempt: 9,244 | TRF Vol: 576,469 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: GTBP — 68.6% short (1.0M / 1.5M)
Short: 996,570 | Exempt: 79,145 | TRF Vol: 1,453,731 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: GTBP — 56.9% short (0.9M / 1.5M)
Short: 860,343 | Exempt: 41,754 | TRF Vol: 1,511,359 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: GTBP — 55.2% short (0.6M / 1.1M)
Short: 605,646 | Exempt: 86,914 | TRF Vol: 1,097,854 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: GTBP — 58.0% short (5.6M / 9.7M)
Short: 5,623,244 | Exempt: 61,323 | TRF Vol: 9,691,537 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
GTBP Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
short_volume
Short Volume: GTBP — 55.1% short (0.4M / 0.7M)
Short: 391,149 | Exempt: 4,939 | TRF Vol: 710,339 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: GTBP — 64.8% short (0.5M / 0.8M)
Short: 532,376 | Exempt: 3,202 | TRF Vol: 821,127 | Short Ratio: 64.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_volume
Short Volume: GTBP — 58.5% short (0.6M / 1.0M)
Short: 584,904 | Exempt: 3,000 | TRF Vol: 998,997 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: GTBP — 57.4% short (0.3M / 0.6M)
Short: 337,999 | Exempt: 25,066 | TRF Vol: 589,314 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: GTBP — 56.8% short (0.3M / 0.6M)
Short: 344,994 | Exempt: 0 | TRF Vol: 607,590 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)